Related references
Note: Only part of the references are listed.Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model
Esak Lee et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Plasma Vascular Endothelial Growth Factors A and C in Patients undergoing Prostatic Biopsy and TURP for Suspected Prostatic Neoplasia
A. N. Singh et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies
Dejan Knezevic et al.
BMC GENOMICS (2013)
Genomic Profiling Defines Subtypes of Prostate Cancer with the Potential for Therapeutic Stratification
Jamie R. Schoenborn et al.
CLINICAL CANCER RESEARCH (2013)
Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays
Maria Tretiakova et al.
HUMAN PATHOLOGY (2013)
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
David C. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort
Matthew R. Cooperberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
R. Joseph Bender et al.
PLOS ONE (2013)
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
Nicholas Erho et al.
PLOS ONE (2013)
Development and validation of a 32-gene prognostic index for prostate cancer progression
Chin-Lee Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Molecular Signature Predictive of Indolent Prostate Cancer
Shazia Irshad et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases
Martin J. Aryee et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Semaphorin 6A regulates angiogenesis by modulating VEGF signaling
Marta Segarra et al.
BLOOD (2012)
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
Emma K. Beardsley et al.
INVESTIGATIONAL NEW DRUGS (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer
Philip J. Saylor et al.
ONCOLOGIST (2012)
Constructing the angiome: a global angiogenesis protein interaction network
Liang-Hui Chu et al.
PHYSIOLOGICAL GENOMICS (2012)
Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2
Tajana Tesan Tomic et al.
PROSTATE (2012)
Semaphorins in Angiogenesis and Tumor Progression
Gera Neufeld et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Signal Transduction by Vascular Endothelial Growth Factor Receptors
Sina Koch et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prognostic value of microvessel density in prostate cancer: a tissue microarray study
Andreas Erbersdobler et al.
WORLD JOURNAL OF UROLOGY (2010)
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Andrea Fontana et al.
CLINICAL CANCER RESEARCH (2009)
Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study
Lorelei A. Mucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Wennuan Liu et al.
NATURE MEDICINE (2009)
Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis
Jeremy B. Burton et al.
CANCER RESEARCH (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma
Christoph W. M. Reuter et al.
WORLD JOURNAL OF UROLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches
Feilim Mac Gabhann et al.
PLOS COMPUTATIONAL BIOLOGY (2006)
Defining aggressive prostate cancer using a 12-gene model
Tarek A. Bismar et al.
NEOPLASIA (2006)
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis
K Jennbacken et al.
PROSTATE (2005)
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
YP Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1
GJ Caine et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
Microvessel density in prostate carcinoma
AV Bono et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2002)
Share Paper
